British Business Bank commits €25M to EQT Health Economics 3 Fund: What it means for UK medtech scale-ups
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s... The fund targets companies that already hold regulatory clearances (CE marking or FDA clearance)...
Published byEdited with DeepSeek-V4-FlashImages generated with GPT Image 1.5
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s...
The fund targets companies that already hold regulatory clearances (CE marking or FDA clearance) and have demonstrated clinical evidence, bridging a well documented funding gap for later stage UK life sciences firms.
Executives cited the need to retain UK innovation, prevent promising companies from relocating for financing, and support technologies that can transform healthcare delivery and reduce system costs.
What was the €25 million commitment from the British Business Bank to EQT Life Sciences' EQT Health Economics 3 Fund, what is the fund's focThe €25M commitment targets commercial-stage medtech and digital health companies that have already secured regulatory clearances.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: What was the €25 million commitment from the British Business Bank to EQT Life Sciences' EQT Health Economics 3 Fund, what is the fund's foc. Article summary: Let me search for more details on the executive quotes and the history of the relationship.. Topic tags: general, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake numbers, clickbait thumbnails, icons, and tiny thumbnail layouts. Make it useful as an illustrative visual, not as factual evi
openai.com
On 17 July 2026, the British Business Bank announced a €25 million (approximately $28.6 million) commitment to EQT Life Sciences' EQT Health Economics 3 Fund (EQT HE3) . The investment, channeled through the Bank's — a £250 million allocation aimed at addressing the funding gap for later-stage UK life sciences companies — marks the by the British Business Bank to EQT Life Sciences as a fund manager .
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "British Business Bank commits €25M to EQT Health Economics 3 Fund: What it means for UK medtech scale-ups"?
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s...
What are the key points to validate first?
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s... The fund targets companies that already hold regulatory clearances (CE marking or FDA clearance) and have demonstrated clinical evidence, bridging a well documented funding gap for later stage UK life sciences firms.
What should I do next in practice?
Executives cited the need to retain UK innovation, prevent promising companies from relocating for financing, and support technologies that can transform healthcare delivery and reduce system costs.
British Business Bank commits €25M to EQT Health Economics 3 Fund: What it means for UK medtech scale-ups
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s... The fund targets companies that already hold regulatory clearances (CE marking or FDA clearance)...
Published byEdited with DeepSeek-V4-FlashImages generated with GPT Image 1.5
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s...
The fund targets companies that already hold regulatory clearances (CE marking or FDA clearance) and have demonstrated clinical evidence, bridging a well documented funding gap for later stage UK life sciences firms.
Executives cited the need to retain UK innovation, prevent promising companies from relocating for financing, and support technologies that can transform healthcare delivery and reduce system costs.
What was the €25 million commitment from the British Business Bank to EQT Life Sciences' EQT Health Economics 3 Fund, what is the fund's focThe €25M commitment targets commercial-stage medtech and digital health companies that have already secured regulatory clearances.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: What was the €25 million commitment from the British Business Bank to EQT Life Sciences' EQT Health Economics 3 Fund, what is the fund's foc. Article summary: Let me search for more details on the executive quotes and the history of the relationship.. Topic tags: general, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake numbers, clickbait thumbnails, icons, and tiny thumbnail layouts. Make it useful as an illustrative visual, not as factual evi
openai.com
On 17 July 2026, the British Business Bank announced a €25 million (approximately $28.6 million) commitment to EQT Life Sciences' EQT Health Economics 3 Fund (EQT HE3) . The investment, channeled through the Bank's — a £250 million allocation aimed at addressing the funding gap for later-stage UK life sciences companies — marks the by the British Business Bank to EQT Life Sciences as a fund manager .
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "British Business Bank commits €25M to EQT Health Economics 3 Fund: What it means for UK medtech scale-ups"?
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s...
What are the key points to validate first?
On 17 July 2026, the British Business Bank committed €25 million (≈$28.6M) to EQT Life Sciences' EQT Health Economics 3 Fund — its first ever commitment to the fund manager — to provide growth capital for commercial s... The fund targets companies that already hold regulatory clearances (CE marking or FDA clearance) and have demonstrated clinical evidence, bridging a well documented funding gap for later stage UK life sciences firms.
What should I do next in practice?
Executives cited the need to retain UK innovation, prevent promising companies from relocating for financing, and support technologies that can transform healthcare delivery and reduce system costs.
The move signals a strategic push to channel institutional capital into commercial-stage medical technology and digital health companies, a segment that often falls into a "valley of death" between early research funding and commercial adoption .
Fund focus: de-risked medtech and digital health
EQT Health Economics 3 (EQT HE3) launched in 2024 and has grown to a total fund size of approximately €216 million. Unlike typical early-stage venture funds, EQT HE3 focuses on commercial-stage, de-risked companies that have already:
Secured established regulatory clearances (e.g., CE marking or FDA clearance)
Demonstrated clinical evidence and product-market fit
Passed clinical and regulatory risk, requiring capital to scale commercial operations rather than validate the technology
The fund targets companies developing medical devices, diagnostics, health technology, and digital health solutions across Europe, with a particular emphasis on UK scale-ups . Portfolio companies already include the UK's Cyted Health (gastrointestinal molecular diagnostics) and Phagenesis.
Organizational history: a new direct relationship
EQT Life Sciences is one of Europe's longest-standing life sciences investors, with a 30-year track record in the sector, having raised over €3.7 billion across 13 private funds and backed more than 150 companies.
The British Business Bank's Life Sciences Investment Programme (LSIP) was launched with a £250 million mandate to catalyse the UK life sciences ecosystem by investing in later-stage companies .
While this €25m commitment to EQT HE3 is the first direct fund-level commitment between the two organizations, the Bank and EQT Life Sciences had previously co-invested in UK health technology companies including Phagenesis and Cyted Health before this fund commitment .
Why this investment? Executive rationale
Leandros Kalisperas, Chief Investment Officer, British Business Bank:
"Supporting UK scale-ups with the finance they need to grow is a vital part of the Bank's mission. The UK is home to a world-class life sciences ecosystem, but companies in this sector often face a funding gap when scaling up. This commitment supports the lifecycle of these companies, providing growth capital for businesses with the potential to transform healthcare delivery."
Christine Hockley, Partner, EQT Life Sciences (co-lead of EQT HE3):
"The UK is home to many of the world's most promising medtech and digital health companies, and we are delighted to have the British Business Bank's support. This commitment will help us back more of these companies as they scale, bringing innovative technologies to patients and healthcare systems."
Mark Andrews, Partner, EQT Life Sciences (co-lead of EQT HE3):
"EQT Life Sciences has a long track record of backing life sciences companies, and this commitment from the British Business Bank will allow us to continue to support the growth of the UK's medtech and digital health sector."
Stated reasons
Reason
Detail
Address the funding gap
UK later-stage life sciences companies often struggle to find sufficient growth capital
Retain UK innovation
Prevent promising UK medtech/digital health companies from relocating to find financing
De-risked investment thesis
Focus on companies with regulatory clearances reduces technology risk
Healthcare transformation
Back technologies that aim to improve outcomes and efficiency in healthcare delivery
Expected impact
The commitment is expected to:
Provide growth capital to multiple UK medtech and digital health scale-ups through the fund
Help bridge the "valley of death" between early-stage innovation and commercial adoption
Strengthen the UK's position as a global hub for life sciences innovation
Channel capital into companies developing products with the potential to transform patient care and deliver cost savings to healthcare systems
A signal to institutional capital
The commitment comes amid broader evidence of a persistent funding gap for later-stage UK life sciences companies, as documented in the Bank's own 2025 Life Sciences Investment Report . The Bank has been ramping up direct investing activity, surpassing £600 million in commitments, with Leandros Kalisperas describing the activity as "a clear signal to UK institutional capital that we want them to join us in backing UK scale-ups" .
By committing to a fund focused on de-risked, regulatory-cleared technologies, the British Business Bank is placing a measured bet on companies that have already passed the most critical technical and clinical hurdles — a strategy that could yield both commercial returns and systemic healthcare improvements.
The move signals a strategic push to channel institutional capital into commercial-stage medical technology and digital health companies, a segment that often falls into a "valley of death" between early research funding and commercial adoption .
Fund focus: de-risked medtech and digital health
EQT Health Economics 3 (EQT HE3) launched in 2024 and has grown to a total fund size of approximately €216 million. Unlike typical early-stage venture funds, EQT HE3 focuses on commercial-stage, de-risked companies that have already:
Secured established regulatory clearances (e.g., CE marking or FDA clearance)
Demonstrated clinical evidence and product-market fit
Passed clinical and regulatory risk, requiring capital to scale commercial operations rather than validate the technology
The fund targets companies developing medical devices, diagnostics, health technology, and digital health solutions across Europe, with a particular emphasis on UK scale-ups . Portfolio companies already include the UK's Cyted Health (gastrointestinal molecular diagnostics) and Phagenesis.
Organizational history: a new direct relationship
EQT Life Sciences is one of Europe's longest-standing life sciences investors, with a 30-year track record in the sector, having raised over €3.7 billion across 13 private funds and backed more than 150 companies.
The British Business Bank's Life Sciences Investment Programme (LSIP) was launched with a £250 million mandate to catalyse the UK life sciences ecosystem by investing in later-stage companies .
While this €25m commitment to EQT HE3 is the first direct fund-level commitment between the two organizations, the Bank and EQT Life Sciences had previously co-invested in UK health technology companies including Phagenesis and Cyted Health before this fund commitment .
Why this investment? Executive rationale
Leandros Kalisperas, Chief Investment Officer, British Business Bank:
"Supporting UK scale-ups with the finance they need to grow is a vital part of the Bank's mission. The UK is home to a world-class life sciences ecosystem, but companies in this sector often face a funding gap when scaling up. This commitment supports the lifecycle of these companies, providing growth capital for businesses with the potential to transform healthcare delivery."
Christine Hockley, Partner, EQT Life Sciences (co-lead of EQT HE3):
"The UK is home to many of the world's most promising medtech and digital health companies, and we are delighted to have the British Business Bank's support. This commitment will help us back more of these companies as they scale, bringing innovative technologies to patients and healthcare systems."
Mark Andrews, Partner, EQT Life Sciences (co-lead of EQT HE3):
"EQT Life Sciences has a long track record of backing life sciences companies, and this commitment from the British Business Bank will allow us to continue to support the growth of the UK's medtech and digital health sector."
Stated reasons
Reason
Detail
Address the funding gap
UK later-stage life sciences companies often struggle to find sufficient growth capital
Retain UK innovation
Prevent promising UK medtech/digital health companies from relocating to find financing
De-risked investment thesis
Focus on companies with regulatory clearances reduces technology risk
Healthcare transformation
Back technologies that aim to improve outcomes and efficiency in healthcare delivery
Expected impact
The commitment is expected to:
Provide growth capital to multiple UK medtech and digital health scale-ups through the fund
Help bridge the "valley of death" between early-stage innovation and commercial adoption
Strengthen the UK's position as a global hub for life sciences innovation
Channel capital into companies developing products with the potential to transform patient care and deliver cost savings to healthcare systems
A signal to institutional capital
The commitment comes amid broader evidence of a persistent funding gap for later-stage UK life sciences companies, as documented in the Bank's own 2025 Life Sciences Investment Report . The Bank has been ramping up direct investing activity, surpassing £600 million in commitments, with Leandros Kalisperas describing the activity as "a clear signal to UK institutional capital that we want them to join us in backing UK scale-ups" .
By committing to a fund focused on de-risked, regulatory-cleared technologies, the British Business Bank is placing a measured bet on companies that have already passed the most critical technical and clinical hurdles — a strategy that could yield both commercial returns and systemic healthcare improvements.
